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Abstract
Analysis of longitudinal family data is challenging because of 2 sources of correlations: correlations across
longitudinal measurements and correlations among related individuals. We investigated whether analysis using
long-term average (average of all 3 visits) can enhance gene discovery compared with a single-visit analysis. We
analyzed all 200 replicates of simulated systolic blood pressure (SBP) in Genetic Analysis Workshop 18 (GAW18)
family data using both single-marker and collapsing methods. We considered 2 collapsing approaches: collapsing
all variants and collapsing low-frequency variants. Analysis using long-term average performed slightly better than
SBP measured at a single visit. Collapsing all variants performed much better than collapsing low-frequency
variants at MAP4 and FLNB, which included a common variant with a relatively large effect. For several variants in
gene MAP4, single-marker analysis also provided high power. In contrast, collapsing only low-frequency variants
performed much better for SCAP, DNASE1L3, and LOC152217, where rare variants in these genes had larger effect
than common variants. However, for other causal variants, all approaches provided disappointingly poor
performance. This poor performance appeared to occur because most of these causal variants explained a very
small fraction of phenotypic variance. We also found that collapsing multiple variants did worse than single-marker
analysis for several genes when they contained causal single-nucleotide polymorphisms (SNPs) with both positive
and negative effects. Because half of causal SNPs were not found in the annotation file based on the 1000
Genomes Project, we found that power was also affected by our use of incomplete annotation information.
Background
Hypertension has been a difficult phenotype for gene
discovery because it is a multifactorial complex phenotype.
Although genome-wide association studies (GWAS) have
successfully identified several genetic variants for many
complex phenotypes, their reliance on common variants
has become a barrier to further progress. Three recent
GWAS consortia [1-3] identified 29 common variants
associated with blood pressure (BP) and hypertension.
However, these variants collectively explain less than 2.5%

of BP variance, and most of the genetic variants remain
yet to be identified (the “missing heritability”). New highthroughput DNA-sequencing technologies now allow us
to seek efficient discovery in both previously identified and
novel genes of multiple rare variants with supposedly
larger effects on BP and hypertension.
Analysis of longitudinal phenotypes in family data has
been a challenge because of 2 sources of correlations:
correlations across longitudinal measurements and correlations among related individuals within families. Analysis
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is often limited to a phenotype measured at a single visit
(the first visit is most commonly used), ignoring the phenotype measured at other visits. Long-term average (LTA)
of BP measurements has shown to be useful in several
genetic epidemiology studies [4,5]. Analysis of LTA is
much simpler than multivariate longitudinal analysis while
using phenotype measured across all visits.
Genetic Analysis Workshop 18 (GAW18) provided
whole genome sequencing (WGS) data in a pedigreebased sample and longitudinal phenotype data for BP and
hypertension. We investigated whether analysis using the
LTA can enhance gene discovery. Because GAW18
sequence data included mostly rare variants, in addition
to single-marker analysis, we applied collapsing methods
that assess the combined effect of multiple variants in
each genomic region. Analyses were performed without
knowledge of the underlying simulation model. However,
we used the GAW18 answers in presenting the results.

Methods
Genotype and phenotype data

We used all 200 replicates of simulated systolic blood
pressure (SBP) phenotype on 847 related individuals.
GAW18 provided sequence data of 959 related individuals (either directly sequenced or imputed) of Mexican
American heritage for more than 8 million variants.
It provided 200 replicates of simulated BP and hypertension phenotypes for 849 individuals. Because the data
included 2 monozygotic twin pairs, we excluded one
from each twin, reducing the sample to 847.
For each individual, we used an LTA of SBP measurements across all three visits. To evaluate the relative
performance of using LTA of SBP, we also analyzed SBP
measurement at visit 1 and visit 3 separately. For covariates of SBP at visit 1 (and 3), we used age, sex, smoking,
body mass index, and medication use at visit 1 (and 3).
For LTA, we used the average values of these covariates.
Because of limited time, we restricted our analysis to
chromosome 3 based on the results from the first replicate
(because chromosome 3 has the largest signal). Chromosome 3 contained 1,200,643 variants that were polymorphic in all 847 individuals. There were 134 causal
variants in 22 genes influencing SBP on chromosome 3.
Annotation files

To apply the collapsing methods, we used the annotation
file that was constructed based on the 1000 Genomes
Project (http://www.sph.umich.edu/csg/abecasis/MACH/
download/1000G-2010-06.html). The annotation file
included 1103 genes on chromosome 3. Because this file
did not include all variants observed in the GAW18 data,
for all 22 causal genes on chromosome 3, we also manually checked the boundaries of these causal genes using
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PubMed. If a variant was contained in multiple genes,
then the variant was used as part of each gene.
Statistical analysis

For family-based data, we extended the proportion test
of Morris and Zeggini [6] to account for family structure. For the combined effect of multiple rare variants
in a genomic region, Morris and Zeggini [6] developed
the proportion test that models the phenotype, in a linear regression framework, as a function of the proportion of rare variants at which an individual carries a
minor allele. For family data, a linear mixed model with
a random polygenic component is commonly used to
account for phenotypic correlations among related individuals. ProbABEL [7] implements this mixed model
approach. Within a gene, we considered 2 collapsing
approaches: (a) collapsing all variants and (b) collapsing
variants with minor allele frequency (MAF) less than
0.05. We used R to construct a collapsing test statistics
in each gene. We used this collapsing test statistics in
conjunction with ProbABEL to account for correlation
among related individuals. We also used ProbABEL for
single-marker analysis.
To evaluate the performance, we computed power
(true-positive) and type I error (false-positive) rates at
level 0.05. For each gene, power was computed by the
proportion of replicates with p-values less than 0.05
over 200 replicates. The overall power was computed by
averaging these values across all 22 causal genes. The
type I error was computed by averaging these values
across all null genes. For single-marker analysis, power
was computed at each variant. The overall power and
type I error were computed by averaging these values
across all 134 causal variants and all null variants,
respectively.

Results
Performance using single-marker approach

Analysis using LTA consistently performed better than
analysis using SBP measured at any single visit. SBP
measured at visit 1 performed slightly better than analysis using SBP measured at visit 3. However, all three
analyses performed poorly in terms of the overall power.
The type I error was about 0.06 (0.057 for SBP1 and
SBP3 and 0.059 for LTA), roughly keeping the level
0.05. Overall power across all 134 causal variants on
chromosome 3 was about 0.12 (0.118, 0.102, and 0.119
for SBP1, SBP3, and LTA, respectively, as shown in
Table 1), which was only about twice as high as the type
I error rate.
The poor performance appeared to be driven by very
small effect sizes of these causal variants. The phenotypic
variance explained by most causal variants was very
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Table 1 Summary statistics of single-marker analysis at
134 causal variants on chromosome 3
MAF

% Variance
SBP

Power
SBP1

Power
SBP3

Power
LTA

Minimum

0.0016 0.00000

0.0050

0.0050

0.0000

1st
quartile

0.0049 0.00001

0.0250

0.0250

0.0150

Median

0.0082 0.00001

0.0350

0.0400

0.0350

3rd
quartile

0.0636 0.00004

0.0925

0.0800

0.1025

Table 3 Spearman correlation across empirical powers at
all causal genes
Correlation

Collapse all
SBP1

Collapse all

SBP1
SBP3
LTA

Collapse rare

SBP1
SBP3

Maximum 0.4947 0.02785

1.0000

1.0000

1.0000

Mean

0.1169

0.1012

0.1179

0.0698 0.00064

LTA, long-term average; MAF, minor allele frequency; SBP, systolic blood
pressure.
The bold text indicates the overall power (power averaged across all 134
causal variants.

small: the third quartile was 0.0004% as shown in Table 1.
The variants at which the empirical power was greater
than 0.5 explained a larger fraction of phenotypic variance
(shown in Table 2). The only exception was the variant at
47958037, which explained almost no phenotypic variance
but power was over 0.87 using all three phenotypes.
Performance using collapsing methods

Collapsing all variants performed better than collapsing
low-frequency variants (with MAF <0.05) across all 22
causal genes. Similar to single-marker analysis, collapsing methods using the LTA performed slightly better
than analysis using SBP measured at any single visit.
Type I errors were 0.07 and 0.06 when collapsing all
variants and low-frequency variants, respectively, also
roughly maintaining the nominal level 0.05. However, all
analyses using collapsing methods performed poorly,
similar to analysis using single-marker approach. The
highest overall power (0.139) was achieved when collapsing all variants using LTA.

Table 2 Causal variants with empirical power over 0
Position

Gene

MAF

% Variance
explained

SBP1 SBP3 LTA

47956424

MAP4

0.3777

0.01426

0.995 0.885 0.990

47957996

MAP4

0.0301

0.01486

1.000 1.000 1.000

47958037

MAP4

0.3420

<1.0E-5

0.980 0.875 0.970

47973345

MAP4

0.0082

0.00049

0.955 0.870 0.975

48040283
48040284

MAP4
MAP4

0.0318
0.0131

0.02785
0.01105

1.000 1.000 1.000
0.775 0.515 0.775

48054461

MAP4

0.1187

0.00030

0.640 0.420 0.670

58109162

FLNB

0.4947

0.00273

0.580 0.510 0.695

141160882 ZBTB38 0.2108

0.00022

0.525 0.315 0.550

141162128 ZBTB38 0.2109

0.00061

0.505 0.310 0.550

LTA, long-term average; MAF, minor allele frequency; SBP, systolic blood
pressure.
Bold text for MAF indicates MAF greater than 0.05; Also bold text for
proportion (%) of variance indicates that with greater than 0.01.

SBP3
0.80

Collapse rare
LTA

SBP1

SBP3

0.94

−0.11

0.18

LTA
0.04

0.86

−0.36
−0.14

0.01
0.13

−0.11
0.04

0.78

0.85
0.91

LTA
Bold text indicates correlation greater than 0.8 between empirical powers of
two approaches.
LTA, long-term average; SBP, systolic blood pressure.

Power at each causal gene varied greatly and depended
on whether low-frequency variants were collapsed or not.
Within each collapsing approach, results were consistent
across three phenotypes (SBP1, SBP3, and LTA), as shown
in Table 3. In contrast, when using rare single-nucleotide
polymorphisms (SNPs), results were considerably different
between 2 collapsing approaches, as shown by low correlations in the upper right block in Table 3.
To understand how power at causal genes depended
on collapsing, we focused on the analysis for LTA phenotype and carefully examined results from 2 collapsing
approaches. Because these collapsing methods are developed for identifying rare variants, we also compared the
results from single-marker analysis by choosing the best
power across all rare SNPs within each gene. Table 4
presents these powers at all 22 causal genes on chromosome 3. We classified these genes into 4 groups. The
first group contains 6 genes, including MAP4 and
FLNB, in which collapsing all variants performed much
better than collapsing low-frequency variants. When collapsing all variants, the highest power was achieved for
gene MAP4 (0.99). This is consistent with the results
from single-marker approach, in which several variants
in MAP4 had high power, as shown in Table 2. The second highest power was achieved for gene FLNB (0.67),
again consistent with single-marker analysis. Except for
TUSC2, all genes in group 1 included a common variant
with a relatively large effect.
The second group in Table 4 contains 6 genes, including SCAP, DNASE1L3, and LOC152217; collapsing only
low-frequency variants performed much better than collapsing all variants. Except for ZBTB38, rare variants in
these genes had larger effect than common variants.
The third group in Table 4 also contains 6 genes,
including CXCR6, in which single-marker analysis performed better than either collapsing approach. Gene
CXCR6 contained one causal variant, and single-marker
analysis performed better. All other genes in group 3
contained causal SNPs with both positive and negative
effects, for which collapsing multiple variants did worse
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Table 4 Empirical power at 0.05 using collapsing and single-marker approaches at all 22 causal genes for long-term
average phenotype
Causal genes

Common
1

2

4

3

Rare

Common

Rare

% Variance explained2
Common

Rare

Empirical Power
Collapse all SNPs

Collapse rare SNPs

Best rare4

MAP4

149

739

3

12

0.01456

0.06336

0.99

0.17

1.00

FLNB
ARHGEF3

321
899

628
1303

1
2

5
8

0.00273
0.00001

0.00007
0.00006

0.69
0.28

0.03
0.07

0.20
0.11

TUSC2

1

9

0

0

ABTB1

7

41

2

0

0.00132

NMNAT3

157

332

3

6

0.00014

0.00017

0.15

0.00

0.09

ZBTB38

175

408

5

4

0.00087

0.00003

0.09

0.15

0.14

DNASE1L3

57

79

4

4

0.00005

0.00026

0.01

0.34

0.08

LOC152217
SCAP

3
31

4
174

1
0

0
2

0.00001
0.00004

0.04
0.03

0.28
0.51

0.05

BTD

72

216

0

8

0.00011

0.03

0.08

0.07

230

452

1

3

0.00002

0.00006

0.02

0.06

0.04

FBLN2
3

Causal SNPs1

Total SNPs

CXCR6

0.21

0.04

0.18

0.02

5

18

0

1

<1.0E-5

0.12

0.03

0.28

PDCD6IP

145

318

2

3

0.00025

0.00003

0.04

0.14

0.15

SUMF1

236

502

1

2

0.00008

<1.0E-5

0.03

0.06

0.16

SENP5

130

275

0

5

0.00007

0.02

0.03

0.12

PTPLB
PPP2R3A

158
198

329
860

1
1

2
11

0.00004
0.00010

0.02
0.02

0.03
0.01

0.10
0.12

SEMA3F

0.00002
<1.0E-5

51

83

0

2

0.00001

0.05

0.03

0.05

TFDP2

363

852

0

5

0.00005

0.04

0.03

0.04

PAK2

294

516

0

0

0.04

0.02

90

126

1

0

0.01

0.00

Overall power

B4GALT4

0.00002

0.139

0.095

Type I error

0.071

0.057

Bold type for % variance indicates 3 largest among common variants and 2 largest among rare variants; bold type for empirical power indicates the highest
across three analysis options.
1
Number of causal single-nucleotide polymorphisms (SNPs) is computed based on the used annotation file (not based on the answers).
2
% Variance explained is computed by adding the percent variance explained by each SNP based on the used annotation file (not based on the answers).
3
Rare SNPs are defined as SNPs with minor allele frequencies (MAFs) less than 0.5.
4
Best rare is the best power across all rare variants in a gene.

than single-marker analysis. The fourth group contained
4 genes, and all methods performed poorly. Although
gene PAK2 did contain 4 causal SNPs in the Answers,
none was used for collapsing approaches because they
were outside the gene in the annotation file based on
the 1000 Genomes Project.

Discussion and conclusions
Analysis of longitudinal phenotypes in family data has
been a challenge because of 2 sources of correlations:
correlations across longitudinal measurements and correlations among related individuals within families. We
applied association analysis using LTA approach to
simulated SBP phenotype in 847 related individuals in
GAW18 family data. Overall, analysis using the LTA
performed slightly better than analysis using SBP measured at any single visit.
Collapsing all variants performed much better than
collapsing low-frequency variants at MAP4 and FLNB,

which included a common variant with a relatively large
effect. For several variants in gene MAP4, single-marker
analysis also provided high power. In contrast, collapsing only low-frequency variants performed much better
for SCAP, DNASE1L3, and LOC152217, where rare
variants in these genes had larger effect than common variants. However, for other causal variants, all approaches
provided disappointingly poor performance. This poor
performance appeared to occur because most of these
causal variants explained very small fraction of phenotypic
variance. We also found that collapsing multiple variants
did worse than single-marker analysis for several genes
when they contained causal SNPs with both positive and
negative effects. Although our results are based on
sequence data from chromosome 3, we expect that our
findings would extend to the GAW18 WGS data.
We adapted Morris and Zeggini’s collapsing (burden)
test to account for family relationship and applied it to
the GAW18 data set of all 847 related individuals. Many
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GAW18 investigators that analyzed only unrelated
individuals (with sample size 142) have observed worse
performance. For example, using the most commonly
used nonburden test sequence kernel association test for
unrelated individuals, overall power across all causal
genes was about 0.05, which was almost identical to the
type I error rate [8]. Our approach of using the averaged
value across multiple measurements reduces variability
across measurements and should enhance gene discovery.
We have not observed much enhancement in this paper.
More sophisticated approaches that fully use all available
measurements such as multivariate longitudinal analysis
may provide better performance.
To apply collapsing methods that assess the combined
effect of multiple variants in a gene, it is necessary to
know which SNPs are contained in the gene. GAW18 performed WGS of 1043 individuals of Mexican American
heritage with an average 60x sequencing depth, with a
goal of finding novel SNPs. However, this creates a problem for applying these rare variant approaches because
available annotation information does not contain these
novel variants. In particular, among 1458 causal SNPs in
the Answers, only 731 SNPs were contained in the annotation file that was constructed based on the 1000 Genomes
Project. We found that our results were affected by our
use of incomplete annotation information. Although the
results and issues that we presented in this paper were
based on GAW18 data, they may be shared with other
sequencing studies.
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